FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

Home / Blog / FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment
FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment
September 04, 2020September 4, 2020
0

The U.S. Food and Drug Administration (FDA) is reviewing a new drug application from Athenex seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast cancer. The application has been granted priority review, and the FDA is expected to make a decision no later than Feb. 28, 2021. The FDA, according to Athenex, it is not currently planning to hold an advisory committee meeting to discuss the application. “We are…

You must be logged in to read/download the full post.

The post FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment appeared first on BioNewsFeeds.